[Results of primary and combined operative-stereotaxic irradiation of pituitary adenomas].
D000239:Adenoma, Acidophil / Q000532:radiotherapy*; D000237:Adenoma, Basophil / Q000532:radiotherapy*; D000238:Adenoma, Chromophobe / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006049:Gold Isotopes / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007495:Iridium / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009026:Mortality; D010759:Phosphorus Isotopes / Q000627:therapeutic use; D010910:Pituitary Irradiation / Q000009:adverse effects; D010911:Pituitary Neoplasms / Q000532:radiotherapy*; D012735:Sexual Dysfunction, Physiological; D013238:Stereotaxic Techniques; D014786:Vision Disorders / Q000209:etiology; D015020:Yttrium Isotopes / Q000009:adverse effects / Q000627:therapeutic use
D006049:Gold Isotopes; D010759:Phosphorus Isotopes; D015020:Yttrium Isotopes; D007495:Iridium
Ergebnisse der primär und kombiniert operativ-stereotaktischen Radioisotopernbestrahlung von Hypophysenadenomen.